{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:32:45Z","timestamp":1761237165591},"reference-count":12,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2004,12,15]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> To determine whether epidermal growth factor receptor (EGFR) expression in non\u2013small-cell lung cancer (NSCLC) is modulated by chemotherapy and to assess the agreement of EGFR status between mediastinal nodes and the primary tumor after chemotherapy. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Patients with NSCLC stage IIIa\/b pN2\/3 confirmed by mediastinoscopy or mediastinostomy were treated with at least three cycles of chemotherapy before undergoing surgery. EGFR expression was evaluated on mediastinal nodes at the time of initial diagnosis and on both the primary tumor and residual metastatic nodes after treatment. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> EGFR expression determined on 138 of 164 patients who underwent mediastinoscopy or mediastinostomy was 0 (22 patients), 1+ (27 patients), 2+ (28 patients), and 3+ (61 patients). Fifty-four patients of 164 received chemotherapy followed by surgery. Of the 89 of 138 patients with EGFR score of 2+\/3+ at the time of diagnosis, 34 patients underwent surgery after induction chemotherapy. None changed to zero EGFR immunoreactivity, with 29 patients (88%) maintaining a score of 2+\/3+. Of the 22 of 138 patients with no EGFR expression at the time of diagnosis, six underwent surgical resection after induction chemotherapy. Of these six patients, four changed their EGFR expression from an EGFR score of 0 to 2+\/3+. After treatment, the agreement of EGFR status between tumor and nodes in the subgroup of patients with EGFR score 2+\/3+ was 89% to 92%. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Our data suggest a very good agreement of EGFR status before and after chemotherapy in EGFR-positive NSCLC. Induction chemotherapy can induce EGFR expression in occasional EGFR-negative tumors. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2004.01.195","type":"journal-article","created":{"date-parts":[[2004,12,21]],"date-time":"2004-12-21T03:02:26Z","timestamp":1103598146000},"page":"4966-4970","source":"Crossref","is-referenced-by-count":29,"title":["Modulation of Epidermal Growth Factor Receptor Status by Chemotherapy in Patients With Locally Advanced Non\u2013Small-Cell Lung Cancer Is Rare"],"prefix":"10.1200","volume":"22","author":[{"given":"Tommaso","family":"De Pas","sequence":"first","affiliation":[{"name":"From the Divisions of Medical Oncology, Pathology, Thoracic Surgery, Epidemiology and Biostatistics, and Radiotherapy, European Institute of Oncology, Milan; and Division of Pharmacology and Chemotherapy, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Pelosi","sequence":"additional","affiliation":[{"name":"From the Divisions of Medical Oncology, Pathology, Thoracic Surgery, Epidemiology and Biostatistics, and Radiotherapy, European Institute of Oncology, Milan; and Division of Pharmacology and Chemotherapy, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"de Braud","sequence":"additional","affiliation":[{"name":"From the Divisions of Medical Oncology, Pathology, Thoracic Surgery, Epidemiology and Biostatistics, and Radiotherapy, European Institute of Oncology, Milan; and Division of Pharmacology and Chemotherapy, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Veronesi","sequence":"additional","affiliation":[{"name":"From the Divisions of Medical Oncology, Pathology, Thoracic Surgery, Epidemiology and Biostatistics, and Radiotherapy, European Institute of Oncology, Milan; and Division of Pharmacology and Chemotherapy, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[{"name":"From the Divisions of Medical Oncology, Pathology, Thoracic Surgery, Epidemiology and Biostatistics, and Radiotherapy, European Institute of Oncology, Milan; and Division of Pharmacology and Chemotherapy, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Elena","family":"Leon","sequence":"additional","affiliation":[{"name":"From the Divisions of Medical Oncology, Pathology, Thoracic Surgery, Epidemiology and Biostatistics, and Radiotherapy, European Institute of Oncology, Milan; and Division of Pharmacology and Chemotherapy, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romano","family":"Danesi","sequence":"additional","affiliation":[{"name":"From the Divisions of Medical Oncology, Pathology, Thoracic Surgery, Epidemiology and Biostatistics, and Radiotherapy, European Institute of Oncology, Milan; and Division of Pharmacology and Chemotherapy, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Noberasco","sequence":"additional","affiliation":[{"name":"From the Divisions of Medical Oncology, Pathology, Thoracic Surgery, Epidemiology and Biostatistics, and Radiotherapy, European Institute of Oncology, Milan; and Division of Pharmacology and Chemotherapy, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"d\u2019Aiuto","sequence":"additional","affiliation":[{"name":"From the Divisions of Medical Oncology, Pathology, Thoracic Surgery, Epidemiology and Biostatistics, and Radiotherapy, European Institute of Oncology, Milan; and Division of Pharmacology and Chemotherapy, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianpiero","family":"Catalano","sequence":"additional","affiliation":[{"name":"From the Divisions of Medical Oncology, Pathology, Thoracic Surgery, Epidemiology and Biostatistics, and Radiotherapy, European Institute of Oncology, Milan; and Division of Pharmacology and Chemotherapy, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Viale","sequence":"additional","affiliation":[{"name":"From the Divisions of Medical Oncology, Pathology, Thoracic Surgery, Epidemiology and Biostatistics, and Radiotherapy, European Institute of Oncology, Milan; and Division of Pharmacology and Chemotherapy, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Spaggiari","sequence":"additional","affiliation":[{"name":"From the Divisions of Medical Oncology, Pathology, Thoracic Surgery, Epidemiology and Biostatistics, and Radiotherapy, European Institute of Oncology, Milan; and Division of Pharmacology and Chemotherapy, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(96)00243-2"},{"key":"R2","unstructured":"Pavelic K, Banjac Z, Pavelic J, et al: Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res 13:1133,1993-1137,"},{"key":"R3","unstructured":"Volm M, Koomagi R, Mattern J: Prognostic value of p16INK4A expression in lung adenocarcinoma. Anticancer Res 18:2309,1998-2312,"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.038"},{"key":"R5","unstructured":"Kris MG, Natale RB, Herbst RS, et al: A phase II trial of ZD1839 (Iressa) in advanced non-small cell lung cancer (NSCLC) patients who failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 21:292a,2002,  (abstr 1166)"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Herbst RS, Kies MS: ZD1839 (Iressa) in non-small cell lung cancer. Oncologist 7:9,2002-15,  (suppl 4)","DOI":"10.1634\/theoncologist.7-suppl_4-9"},{"key":"R7","unstructured":"Sirotnak FM, Zakowski MF, Miller VA, et al: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6:4885,2000-4892,"},{"key":"R8","unstructured":"Wakeling AE, Guy SP, Woodburn JR, et al: ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62:5749,2002-5754,"},{"key":"R9","unstructured":"Bailey LR, Kris M, Wolf M, et al: Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib (\u2032Iressa\u2019, ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer: IDEAL 1 and 2. Proc Am Assoc Cancer Res 44:1362,2003,  (abstr LB-170)"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Cortes-Funes H, Soto Parra H: Extensive experience of disease control with gefitinib and the role of prognostic markers. Br J Cancer 89:S3,2003-8,  (suppl 2)","DOI":"10.1038\/sj.bjc.6601476"},{"key":"R11","unstructured":"Sato JD, Kawamoto T, Le AD, et al: Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1:511,1983-529,"},{"key":"R12","unstructured":"Mendelsohn J: Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 3:2703,1997-2707,"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2004.01.195","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:22:18Z","timestamp":1653510138000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2004.01.195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12,15]]},"references-count":12,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2004,12,15]]}},"alternative-id":["10.1200\/JCO.2004.01.195"],"URL":"https:\/\/doi.org\/10.1200\/jco.2004.01.195","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12,15]]}}}